A 204197
Alternative Names: A-204197Latest Information Update: 24 Jan 2013
Price :
$50 *
At a glance
- Originator Abbott Laboratories
- Class Antineoplastics
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 01 Jan 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 21 Sep 2000 New profile
- 21 Sep 2000 Preclinical development for Cancer in USA (Unknown route)